10x Genomics (NASDAQ:TXG) Q4 results:
Revenue: $75.3M (+49%).
2019 revenue: $245.9M (+68%).
Cumulative Chromium instruments sold: 1,666.
Net loss: ($7.1M); loss/share: ($0.07).
2020 guidance: Revenue: $350M – 360M (consensus: $346M).
Shares down 5% after hours in apparent response to the lower expected growth rate versus 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.